Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Scholar Rock Holding Corp SRRK

Healthcare Biotechnology
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled the Company... see more

Recent & Breaking News (NDAQ:SRRK)

Scholar Rock Reports Second Quarter 2019 Financial Results and Highlights Business Progress

GlobeNewswire August 14, 2019

Scholar Rock to Present at the 2019 Wedbush PacGrow Healthcare Conference

GlobeNewswire August 7, 2019

Scholar Rock Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock in Public Offering

GlobeNewswire July 2, 2019

Scholar Rock Announces Pricing of Public Offering of Common Stock

GlobeNewswire June 19, 2019

Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference

GlobeNewswire June 19, 2019

Scholar Rock Announces Proposed Public Offering of Common Stock

GlobeNewswire June 18, 2019

Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers

GlobeNewswire June 3, 2019

Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference

GlobeNewswire May 28, 2019

Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress

GlobeNewswire May 14, 2019

Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy

GlobeNewswire May 8, 2019

Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors

GlobeNewswire April 30, 2019

Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy

GlobeNewswire April 2, 2019

Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress

GlobeNewswire March 18, 2019

Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance

GlobeNewswire March 12, 2019

Scholar Rock to Participate in Upcoming Investor Conferences

GlobeNewswire March 6, 2019

Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans

GlobeNewswire February 26, 2019

Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2019

Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

Business Wire December 19, 2018

Scholar Rock Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for SRK-015 for the Treatment of Spinal Muscular Atrophy

GlobeNewswire December 3, 2018

Scholar Rock to Present at the BMO 2018 Prescriptions for Success Healthcare Conference

GlobeNewswire November 29, 2018